Novartis announced that an oral multiple sclerosis drug achieved its main goal in late-stage studies, with shares rising on the news. The company separately paused autoimmune cell therapy studies following patient deaths. An unverified claim that the pill outperformed older treatments appeared in one report.
Trial success offers hope but market reactions highlight prioritization of investor returns over access and safety.
“Systemic incentives in drug development favor shareholders”
Market-driven innovation delivers results and self-corrects on safety without excessive regulation.
“Private-sector competition produces therapies and accountability”
Oral options expand patient choice and autonomy; firms respond quickly to evidence via reputation incentives.
“Decentralized development outperforms top-down mandates”
All views overlook actual endpoint definitions, drug identity, and missing comparators that determine real value.
“Shared narrative rests on unexamined clinical magnitude and source limitations”